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Abstract
Background: The accuracy of screening for anal cancer precursors relative to screening for cervical cancer precursors has
not been systematically examined. The aim of the current meta-analysis was to compare the relative accuracy of anal
cytology to cervical cytology in discriminating between histopathologic high grade and lesser grades of dysplasia when the
reference standard biopsy is obtained using colposcope magnification.
Methods and Findings: The outcome metric of discrimination was the receiver operating characteristic (ROC) curve area.
Random effects meta-analysis of eligible studies was performed with examination of sources of heterogeneity that included
QUADAS criteria and selected covariates, in meta-regression models. Thirty three cervical and eleven anal screening studies
were found to be eligible. The primary meta-analytic comparison suggested that anal cytologic screening is somewhat less
discriminating than cervical cytologic screening (ROC area [95% confidence interval (C.I.)]: 0.834 [0.809–0.859] vs. 0.700
[0.664–0.735] for cervical and anal screening, respectively). This finding was robust when examined in meta-regression
models of covariates differentially distributed by screening setting (anal, cervical).
Conclusions: Anal cytologic screening is somewhat less discriminating than cervical cytologic screening. Heterogeneity of
estimates within each screening setting suggests that other factors influence estimates of screening accuracy. Among these
are sampling and interpretation errors involving both cytology and biopsy as well as operator skill and experience.
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Introduction
The accuracy of screening procedures for anal cancer and its
precursors relative to comparable procedures used in screening for
cervical cancer and its precursors has not been systematically
defined. The issue is of importance because invasive anal cancer
rates are increasing among HIV-infected persons[1,2] and because
screening programs modeled on procedures used in cervical
cancer screening are being increasingly implemented among
persons at increased risk for anal cancer[3]. The primary objective
of this study was to meta-analytically compare a summary
operating characteristic of the performance of cervical and anal
cytology testing in the detection of cervical and anal cancer and
their precursors, when the reference standard biopsy is obtained at
colposcopy or high resolution anoscopy (HRA), respectively.
Methods
Data Sources and Searches
Cervical. Data sources included: (1) MEDLINE from 2000
through 2010; (2) review of two previously published meta-analyses
of cervical cytology accuracy.[4,5] The MEDLINE search strategy
included the following search terms in any field: cervical cytology AND
sensitivity AND specificity AND cervical intraepithelial neoplasia AND year
of publication 2000-2010. Searches were limited to English-language
publications. Unpublished studies were ineligible for inclusion.
Authors were not contacted to provide data in the eligible format if
the published manuscript had incomplete data for analysis.
Anal. Data sources included: (1) MEDLINE from 1990 through
2010; (2) review of published systematic reviews [6–9]. Because the
search algorithm comparable to that used for cervical publications
yielded only 33 potentially relevant publications, the search strategy
for anal publications was broadened. The MEDLINE search included
the following search strategy in any field: (anal cancer OR anal dysplasia
OR anal cytology OR anal intraepithelial neoplasia)A N Dscreening AND
((sensitivity AND specificity)O Raccuracy). Unpublished and non-English
language publications were ineligible for inclusion. When a
publication appeared to be eligible for inclusion but the data
presented in the manuscript was incomplete, authors were
contacted to request data in the required format (see below).
Study Selection
In establishing study inclusion and exclusion criteria we used the
following definitions of index and reference tests. The index test was
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cytology swabs or brushes and processing of the samples using
either traditional slide fixation or liquid cytologic media. The
reference standard was defined as colposcope magnified and directed
punch biopsy of the uterine cervix or anal canal, respectively.
Operator visual impression without a biopsy could not be included as
part of the definition of the reference standard result. Inclusion
criteria included published reports: (1) of primary screening or
follow up evaluation for previous cytologic abnormalities; (2) use of
the Bethesda 1991 or 2001 Classification System (or equivalent);
(3) reference standard diagnosis by cervical or anal punch biopsy
obtained using colposcope magnification; the addition of endo-
cervical curettage sampling was allowed for colposcopy studies; (4)
average time interval between cytology and punch biopsy #3
months; (5) availability of extractable data in the format below
(Table 1), where ‘‘cases’’ are defined as those with histopathologic
evidence by punch biopsy (cervical or anal) of cervical or anal
intraepithelial neoplasia 2 (CIN 2 or AIN 2) or greater and
cytology diagnostic categories include negative (‘‘no atypical or
malignant cells’’), atypical squamous cells of uncertain significance
(ASCUS), atypical squamous cells can’t rule out high grade (ASC-
H), low grade squamous intraepithelial lesion (LSIL), and high
grade intraepithelial lesion (HSIL):
Exclusion criteria included: (1) reference standard established
only by visual inspection at colposcopy or anoscopy without
biopsy; (2) patients with normal colposcope magnified visual
impression but no biopsy were classified as normal histology; (3)
cervical cytology study sample explicitly included patients
previously treated by conization or LLETZ (because of unavail-
ability of comparable study populations for anal cytology studies).
Data Extraction
In abstracting cytology data from the included publications, the
following conventions were followed: (1) inflammatory changes
were categorized with the ‘‘negative’’ category; (2) AGUS was
categorized with ASCUS; (3) HPV changes or koilocytes were
classified under LSIL; (4) the category ‘‘$HSIL’’ included ASC-H,
HSIL, CIS, and invasive carcinoma.
The main outcome measure was the receiver operating character-
istic (ROC) curve area estimated from the extracted 2 by 4 data
tables, wherein the cytology diagnostic categories are treated as
ordinal measures and the reference standard is binary. An ROC
metric to summarize the ability of cervical (anal) cytology to
discriminate between $CIN 2 (AIN 2) and , CIN 2 (AIN 2)
histology has been previously used [10–12] and has the advantage
of not being cut point dependent.
Each identified publication was reviewed by a single reviewer
(WCM) and classified as ineligible or potentially eligible based on
review of the title and abstract. When ineligibility was in doubt,
full reports were reviewed for a final determination. Full reports of
potentially eligible publications were then independently reviewed
by two investigators. Final eligibility determination was based on
consensus of the two reviewers. Decisions regarding final eligibility
for inclusion were made without knowledge of the cytology ROC
area, which is the primary outcome metric of the meta-analysis.
Validity Assessment: Study Quality and Covariate Rating
Eligible publications were reviewed using the QUADAS tool
[13–15]. Further specification of quality and covariate review
criteria was operationalized using the following additional
questions:
(1) Were patients undergoing the reference standard procedure
(colposcopy or HRA directed punch biopsy) selected on the
basis of prior screening cytology results? (Yes/No/Unclear)[-
verification bias]
(2) What was the time interval between the test cytology and the
reference standard procedure? (same day/ not same day but
within 3 months/Unclear)[disease progression bias]
(3) Was the reference standard result based only on punch biopsy
interpretation? (punch biopsy only/composite of punch biopsy
and colposcopy-HRA visual impression/mixture of punch
biopsy and other histology/Unclear)[reference standard
definition]
(4) What cytology method was used? (Conventional/Thin Prep/
Other liquid cytology/Unclear)
(5) Were histologic and/or cytologic results reviewed for final
classification by central adjudication or independent readers?
(Yes/No/Unclear)
(6) Did the study sample explicitly include HIV infected patients?
(Yes/No/Unclear)
(7) What was the study design? (Clinical Cohort/Case Control/
Convenience sample of matched cytology and histology
results/Clinical Trial/Other/Unclear)
(8) What cytology classification system was used? (Bethesda
1991/Bethesda 2001/Other comparable/Other not compa-
rable/Unclear)
The study quality review was separately scored by two co-
authors (WCM and WA). Discordant ratings were resolved by
consensus. Initial agreement (prior to consensus review) among
reviewers was summarized using the prevalence and biased
adjusted kappa statistic (PABAK)[16] implemented in WinPEPI
version 11.4.[17]
Data Synthesis and Analysis
For each eligible and included study, the diagnostic ROC area
was estimated from extracted 2 by 4 raw frequency tables using the
roctab procedure in Stata version 11.2 (StataCorp, College Station,
TX). Estimated ROC areas with their standard errors (s.e.) were
then pooled using the random effects model of DerSimonian and
Laird[18] as implanted in the Stata metan procedure. The primary
analysis included all eligible studies. A secondary planned analysis
was performed conditioning on two factors that may influence
comparability of the two screening contexts: (1) the time interval
between most recent cytology and biopsy; and (2) the operative
method for obtaining the histology reference standard. For this
secondary analysis, included studies were limited to those
reporting both same day cytology and histology reference standard
based exclusively on colposcope directed punch biopsy.
Heterogeneity of effects was evaluated using the I
2-statistic[19]
and further explored with funnel plots graphing ROC area against
s.e.(ROC) to detect asymmetry suggesting bias. The Egger test was
performed as a quantitative test of skewness in the funnel plot.[20]
Finally, we performed random effects meta-regression as imple-
Table 1. Data format extracted for each included study in the
present meta-analysis.
Cytology
Biopsy Negative ASCUS LSIL $HSIL or ASC-H
$CIN 2 (AIN 2)
,CIN 2 (AIN 2)
doi:10.1371/journal.pone.0024946.t001
Comparison of Cervical & Anal Dysplasia Screening
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24946mented using the Stata metareg procedure including as covariates
those QUADAS and covariate measures that were differentially
distributed across screening setting (p,0.20) in contingency table
analysis. Covariates found to be associated with the ROC outcome
(p,0.05) in metagression models jointly adjusted for screening
setting (cervical, anal) were used as stratification factors to estimate
the effect of screening setting (cervical, anal) within levels of the
same covariates.
Results
Trial Flow: Cervical Cytology-Biopsy Studies
From the MEDLINE search algorithm for cervical studies, 931
unduplicated publications were initially identified. Primary reasons
for exclusion of 884 publications on initial screen included: (1) lack
of relevance to the research question; (2) incomplete data for
analysis evident by review of abstract; and (3) use of cytology
system not comparable to Bethesda system. The remaining 47
publications were judged to be potentially eligible for study
inclusion, and their manuscripts were independently reviewed for
final determination of eligibility by two investigators (WCM and
WA). Of these, 14 were excluded for the following reasons (more
than one may apply to each study): (1) non-biopsied patients were
classified as having normal histology if colposcopic appearance
was normal (n=4); (2) cytology-biopsy interval either not stated or
exceeded average of 3 months (n=8); (3) reported data aggregated
across cytology categories (n=2); (4) cytology classification not
comparable to Bethesda system (n=1); and (5) substantial missing
data (31/52) with small sample size (n=1). The thirty three
remaining studies met eligibility criteria and were included
(Figure 1).
Trial Flow: Anal Cytology-Biopsy Studies
From the MEDLINE search strategy for anal publications, 627
unduplicated publications were initially identified. Of these, 605
were excluded on preliminary screen. Primary reasons for
exclusion included: (1) lack of relevance to the research question;
(2) lack of primary data (e.g. review articles); (3) incomplete data
collected as evident from review of the abstract (e.g. investigators
did not use colposcopic magnification or range of studied cytology
results restricted). The remaining 22 studies were judged to be
potentially eligible. Of the 22, 11 were excluded after detailed
review and attempts to contact authors for clarification or data.
Nine authors were emailed with requests to provide data in the
required format. Of the 9, 4 responded and 1 was able to provide
eligible data. Reasons for final exclusion of the 11 studies (more
than one category may apply to each study) were: (1) incomplete
data for analysis (n=8); (2) cytology-biopsy interval either not
stated or exceeded average of 3 months (n=5); (3) HRA not
performed in all reported cases (n=2); and (4) cytology
classification not comparable to Bethesda system (n=1). The final
number of included eligible studies was eleven (Figure 2).
Study Characteristics: Study Quality and Covariate
Review
PABAK agreement (median [range]) between the two primary
study reviewers on QUADAS item scoring was 0.72 [0.44 – 0.94]
and 0.73 [0 – 0.82], for cervical and anal cytology studies,
respectively. PABAK was not estimable for those items for which
reviewers uniformly chose a single rating option. Consensus
QUADAS ratings by study category (cervical or anal) are
presented in Figure 3. Reviewers judged that study participants
were selected based on prior cytology screening results in 58% and
27% (p=0.192) of cervical and anal cytology studies, respectively.
There was no difference in the distribution of cytology-biopsy time
intervals comparing cervical to anal studies, with 71% and 82%
(p=0.774) of studies reporting same day cytology and biopsy
measures, respectively. With regard to the histological reference
standard, 91% of anal studies reported exclusive use of HRA
directed punch biopsy whereas 65% of the cervical studies
reported exclusive use of colposcopically directed punch biopsy
(p=0.344). The most common additional histological reference
standard component included in the cervical studies was
endocervical curettage. There was no difference in reported
cytological method between the two study types with 65% and
64% (p=0.364) of cervical and anal studies reporting use of
conventional cytology, respectively. Only 3% of cervical studies
reported on HIV-infected participants, whereas 100% of anal
studies included (not necessarily exclusively) HIV infected persons.
By study design, 80% of the cervical studies were cohort designs in
comparison 91% of anal studies; 12% and 9% of cervical and anal
studies, respectively, were cross sectional studies involving
matching of available cytology to biopsy results. The Bethesda
1991 cytology system was reported in 71% and 36% (p=0.12) of
cervical and anal studies, respectively. This difference reflects the
more recent publication of HRA studies.
Figure 1. Flow of Included Studies: Cervical Screening.
doi:10.1371/journal.pone.0024946.g001
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Table S1 presents the data extraction results and summary
metric (cytology-biopsy ROC area) organized by study type
(cervical and anal). The primary analysis (Figure 4) comparing the
ability of cervical and anal cytology to discriminate between high
grade and non-high grade histology by colposcope directed biopsy
suggested superiority for cervical screening (ROC area [95% C.I.]:
0.834 [0.809 – 0.859] vs. 0.700 [0.664 – 0.735] for cervical and
anal screening, respectively). While heterogeneity of effect was
evident among studies for both screening contexts, it was greater
among cervical screening studies (I
2 statistic 92.3%, p,0.0001 for
cervical studies and 53.8%, p=0.017 for anal studies). This
difference in heterogeneity across screening context is also evident
in the funnel plots (Figure 5), which demonstrate that relatively
more of the cervical screening studies fall outside the pseudo 95%
confidence intervals than is observed for the anal screening studies.
The relative symmetry of both funnel plots is supported by the
non-significant Egger test for both.
When the analysis was restricted to those studies reporting both
concurrent (same day) cytology and biopsy and also reporting
histology reference standard obtained exclusively using punch
biopsy (excluding endocervical curettage), the difference between
screening contexts was greater than that estimated for the
unrestricted primary analysis (ROC area [95% C.I.]: 0.871
[0.844 – 0.899] vs. 0.690 [0.649 – 0.732] for cervical and anal
screening, respectively).
The distributions of the following QUADAS items and
covariates were differential (p,0.20) in contingency table analyses
of study characteristics and screening setting: (1) QUADAS 5
(partial verification bias)[p=0.071], (2) QUADAS 10 (index test
blinded)[p=0.082], (3) patients referred for biopsy on the basis of
prior screening cytology [p=0.087],(4) HIV-infected patients
included in study [p,0.0001], and (5) the cytology classification
system used [p=0.092]. Each of these five characteristics was
entered as a categorical indicator in separate random effects meta-
regressions that included also screening setting (cervical, anal) to
identify those that were explanatory of heterogeneity in estimated
ROC outcome. Of these five study characteristics, only the item
dealing with referral for colposcope directed biopsy conditional
upon screening cytology results was significantly associated with
estimates of ROC heterogeneity in random effects meta-regression
models (Table 2, Model 3). It is also evident in Table 2 that, with
the exception of Model 4 (HIV+ patients included), the estimated
effect of screening setting remained statistically significant and in
all models consistent with the overall effect screening setting
favoring cervical screening over anal screening. Regarding Model
4, it should be noted that only 1 of 32 cervical screening studies
explicitly included HIV infected patients whereas all 11 of the anal
screening studies included HIV infected patients. So the effect of
screening setting was strongly confounded with the HIV covariate.
Because Model 3 (referral for biopsy conditional upon screening
cytology results) suggested that conditional referral was associated
with at least part of the observed effect heterogeneity in the
primary meta analytic result, we re-estimated the screening setting
effects for each of the three rating options for conditional referral
(yes, no, unclear). The estimated pooled ROC effects for screening
setting restricting eligibility to those studies for which the
conditional referral item was rated ‘‘yes’’ were: 0.797 (95% CI:
0.771–0.822) for cervical screening (n=19 studies) and 0.749
(0.699–0.798) for anal screening (n=3 studies), with associated I
2
heterogeneity estimates of 86.3% and 37.3%, respectively. The
corresponding pooled ROC effect estimates restricting eligibility to
studies for which the conditional referral item was rates ‘‘no’’ were:
0.898 (0.865–0.931) for cervical screening (n=10 studies) and
0.657 (0.621–0.694) for anal screening (n=6 studies), with
associated I
2 estimates of 74.9% and 0%, respectively. Finally
for the conditional referral rating of ‘‘unclear’’ for which there
were only 4 eligible cervical and 2 eligible anal studies, the
corresponding pooled ROC estimates were 0.868 (0.785–0.951)
and 0.716 (0.618–0.813) with I
2 estimates of 91.8% and 77.5%,
respectively. Thus, in these exploratory analyses based on meta-
regression results, non-overlapping ROC confidence intervals
were observed only for the conditional referral category of ‘‘no’’
while the subgroup study sample size was considerably reduced for
each restricted comparison.
Discussion
To our knowledge, this study is the first attempt to
systematically compare the relative accuracy of anal and cervical
screening for cancer precursors. In the primary meta-analysis of 33
cervical and 11 anal screening studies, we found that anal cytologic
screening appeared to be somewhat less discriminating than
cervical cytologic screening for detecting high grade histopatho-
logic lesions ($CIN 2 or AIN 2): (1) when the index of
Figure 2. Flow of Included Studies: Anal Screening.
doi:10.1371/journal.pone.0024946.g002
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characteristic (ROC) curve; (2) when the reference standard biopsy
is obtained using colposcope magnification; and (3) when the
interval between cytology and biopsy is less than or equal to 3
months. This conclusion was robust when restricting study
eligibility by requiring that cytology and histology be ascertained
on the same day using only punch biopsy to obtain the reference
standard diagnosis. Although there was considerable heterogeneity
among both cervical and anal screening studies (more so among
cervical studies), we found that the primary result was confirmed in
meta-regression models controlling for those study quality
indicators and covariates that were differentially associated with
screening setting (cervical, anal).
A number of factors may account for or contribute to the
primary meta-analytic finding. First is the possibility that the
currently used screening procedures for anal cancer and its
precursors are intrinsically less accurate than the comparable
procedures for cervical screening. Cytology is obtained blindly in
anal screening and under direct visualization in cervical screening.
In addition, obtaining the reference standard biopsy is more
challenging in the anal canal because of the collapsing nature of
the organ such that lesions may be obscured by tissue folds not
adequately retracted [21].
However before concluding intrinsic inferiority of anal
screening, sources of bias in the conduct of the meta-analysis
must be examined. First, our study selection procedures differed
by screening setting as discussed in the Methods section. We used
expanded MEDLINE search terms to initially identify potentially
eligible anal screening studies because of the low yield when
applying the terms used to identify cervical screening studies.
Second, we contacted authors for clarifying information and for
formatted data for the potentially eligible anal studies but not for
the cervical studies. Third, the response rate from contacted
authors of anal screening studies was low. Fourth, we excluded
studies (both cervical and anal) that examined other metrics of
cytology screening performance (sensitivity, specificity, predictive
value) when data inadequate to estimate our ROC metric were
either not published or not made available upon data request (in
the case of anal studies). We do not know whether these
procedural decisions resulted in biased study selection and
estimation of effects. However we required that decisions
regarding study selection were made prior to estimating study
ROC outcomes. Furthermore, examination of the funnel plot
symmetry and non-significant Egger tests provide some support
for a conclusion that selection of publications was not seriously
biased.
Figure 3. Consensus QUADAS ratings by study category (Cervical or Anal).
doi:10.1371/journal.pone.0024946.g003
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doi:10.1371/journal.pone.0024946.g004
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doi:10.1371/journal.pone.0024946.g005
Table 2. Meta-Regression Estimates of Joint Effects of Screening Setting and Selected Covariates (n=44 studies).
Model Covariate b[covariate] s.e.[covariate p[covariate]
b[screening
setting3]
s.e.[screening
setting]
p[screening
setting]
1 QUADAS 51 [reference=yes] --
QUADAS 5=no -0.028 0.034 0.419 -0.132 0.03 ,0.0001
2 QUADAS 102 [reference: yes] --
QUADAS 10= unclear 0.2 0.025 0.445 -0.143 0.03 ,0.0001
3 Conditional referral for
biopsy [reference: yes]
0.045
no 0.061 0.026 0.023 -0.153 0.028 ,0.0001
unclear 0.061 0.035 0.085
4 HIV+ patients included
[reference: yes]
--
no 0.016 0.112 0.885 -0.121 0.114 0.296
5 Cytology Classification System
[reference: Bethesda 1991]
-- 0.836
Bethesda 2001 -0.01 0.029 0.726 -0.131 0.032 ,0.0001
Other comparable -0.032 0.059 0.588
1. QUADAS 5. Partial verification avoided.
2. QUADAS 10. Index test results blinded.
3. Screening setting: anal. Reference: cervical.
doi:10.1371/journal.pone.0024946.t002
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Jones (1996), far exceeded the sample sizes of all other included
studies and would have dominated the analysis using a fixed effect
weighting procedure. The median [range] sample sizes for the
anal and cervical studies were 169 [75, 401] and 448 [54, 21616].
We chose random effects meta-analysis in order to allow
estimation of the true effect to vary between studies and to give
relatively greater weight to smaller studies.[22] The primary meta-
analytic result was concordant for both random and fixed effect
models; the pooled fixed effect ROC estimates (95% CI) for anal and
cervical screening studies were 0.708 (0.685–0.731) and 0.823
(0.818–0.828), respectively.
Although a few of the included studies addressed the issue of
verification bias, the raw data abstracted from all included studies
was unadjusted for verification bias. The study raters judged that
58% of included cervical screening studies and 27% of anal studies
were subject to potential verification bias in that referral for
colposcopy or HRA was conditional upon screening cytology
results. Although conditional referral was identified in meta-
regression analysis as significantly associated with ROC heteroge-
neity (Table 2, Model 3), controlling for it did not alter the primary
meta-analytic result.
If one accepts our meta-analytic ROC estimates as valid, what
conclusions can be drawn regarding screening for anal cancer
precursors? First, we believe that the finding of somewhat less
discriminatory ability for anal cytology than for cervical cytology
does not diminish the rationale for anal cancer screening. The
rationale has been argued cogently with an accumulating evidence
base[7,23] on the basis of accepted criteria for public health
screening[24], albeit with considerable uncertainty regarding the
efficacy of treatments for anal cancer precursors identified through
screening and also regarding screening logistics (who to screen,
how to screen, how often to screen).[8] Second, experience with
performing anal cytology and HRA is much more limited and
recent than comparable experience screening for cervical cancer
and its precursors. It is known that operator experience makes a
difference [25] and HRA investigators and practitioners are still
learning to optimize techniques.[26,27] Heterogeneity of ROC
estimates may in part reflect operator experience and skill such
that the ceiling for accuracy of combined screening with cytology,
HRA, and biopsy components may not yet have been achieved.
Third, studies of accuracy of both cervical and anal screening
procedures should take into account the fact that the reference
standard of punch biopsy is itself an imperfect reference standard
subject to sampling and interpretation error[28] just as is the case
for cytological screening.[21] Fourth, a recent cost-effectiveness
analysis of screening for anal cancer precursors in HIV-infected
men having sex with men concluded that direct use of HRA was
the most cost-effective strategy for detecting AIN 2/3 that high risk
population.[29] It is our view, however, that because that
conclusion assumed that HRA directed biopsy was itself a perfect
reference standard and did not take into account the potential
value of repeated cytological examination combined with digital
rectal examination, our finding of somewhat less discriminating
performance of anal cytology in comparison with cervical cytology
does not of itself support a recommendation to eliminate prior
cytology screening as a component of screening for anal cancer
precursors in high risk populations. In conclusion, we believe that
our results better define the relative accuracy of screening for anal
cancer precursors and contribute to ongoing policy discussions
regarding formulation of guidelines regarding anal cancer
screening in populations at risk.
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